Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体,为预防绝经
骨质疏松症
。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体,为预防绝经
骨质疏松症
。
明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症药物。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工,
表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性受体调节剂,为预防绝经
骨质疏松症药物。
声明:以、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝骨质疏松症药物。
声明:以上例句、词性分类均由互网资源自动生成,部分未
工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预松症药物。
声明:以上例句、词性分类均由互联网资源自动生成,部分未过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体,为预防绝经
骨质疏松症
。
明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯是一种选择性雌激素受体调节剂,为预防绝经
骨质疏松症药物。
声明:以上例句、词性分类均由资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症药物。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审,
达内容亦不代
本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症药物。
声明:以上例句、词性分类均由互网资源自动生成,部分未经过
核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症药
。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表亦不代表本软件的观点;若发现问题,欢迎向我们指正。